Illumina (ILMN) Raised to “Buy” at Citigroup

Citigroup upgraded shares of Illumina (NASDAQ:ILMN) from a neutral rating to a buy rating in a research report released on Monday, Marketbeat Ratings reports. They currently have $275.00 price target on the life sciences company’s stock, up from their prior price target of $260.00.

A number of other research firms also recently commented on ILMN. BidaskClub downgraded shares of Illumina from a buy rating to a hold rating in a research report on Saturday, February 3rd. Barclays lifted their target price on shares of Illumina from $200.00 to $215.00 and gave the stock an equal weight rating in a research report on Wednesday, January 31st. Morgan Stanley lifted their target price on shares of Illumina from $145.00 to $157.00 and gave the stock an underweight rating in a research report on Wednesday, January 31st. Leerink Swann lifted their target price on shares of Illumina from $250.00 to $276.00 and gave the stock an outperform rating in a research report on Wednesday, January 31st. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $265.00 target price (up previously from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $241.39.

Illumina (ILMN) opened at $221.20 on Monday. Illumina has a 1-year low of $158.02 and a 1-year high of $248.97. The firm has a market cap of $32,300.00, a P/E ratio of 44.87, a P/E/G ratio of 2.82 and a beta of 0.92. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.99 and a quick ratio of 3.55.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The company had revenue of $778.00 million during the quarter, compared to analyst estimates of $752.04 million. During the same period in the previous year, the business earned $0.85 EPS. The firm’s revenue for the quarter was up 25.7% on a year-over-year basis. analysts anticipate that Illumina will post 4.59 earnings per share for the current year.

In other news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.55, for a total transaction of $283,187.50. Following the completion of the sale, the director now owns 9,088 shares of the company’s stock, valued at approximately $2,058,886.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $225.33, for a total transaction of $32,672.85. Following the completion of the transaction, the senior vice president now directly owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The disclosure for this sale can be found here. In the last three months, insiders have sold 116,922 shares of company stock valued at $25,811,809. Insiders own 0.89% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Advisory Services Network LLC boosted its holdings in Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after buying an additional 89 shares during the period. Raymond James Financial Services Advisors Inc. boosted its holdings in Illumina by 2.1% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 5,698 shares of the life sciences company’s stock worth $989,000 after buying an additional 116 shares during the period. Hemenway Trust Co LLC boosted its holdings in Illumina by 0.6% in the 4th quarter. Hemenway Trust Co LLC now owns 37,895 shares of the life sciences company’s stock worth $8,280,000 after buying an additional 227 shares during the period. Daiwa Securities Group Inc. boosted its holdings in Illumina by 4.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock worth $1,211,000 after buying an additional 229 shares during the period. Finally, Private Asset Management Inc. boosted its holdings in Illumina by 2.2% in the 4th quarter. Private Asset Management Inc. now owns 11,072 shares of the life sciences company’s stock worth $2,419,000 after buying an additional 240 shares during the period. 92.09% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2018/02/08/illumina-ilmn-raised-to-buy-at-citigroup.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit